154 related articles for article (PubMed ID: 19068390)
1. [Molecular biology and prostate cancer: evolution or revolution?].
Molinié V; Beuzeboc P; Mahjoub WK;
Ann Pathol; 2008 Oct; 28(5):354-62. PubMed ID: 19068390
[TBL] [Abstract][Full Text] [Related]
2. [Fusion genes and prostate cancer. From discovery to prognosis and therapeutic perspectives].
Beuzeboc P; Soulié M; Richaud P; Salomon L; Staerman F; Peyromaure M; Mongiat-Artus P; Cornud F; Paparel P; Davin JL; Molinié V
Prog Urol; 2009 Dec; 19(11):819-24. PubMed ID: 19945666
[TBL] [Abstract][Full Text] [Related]
3. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.
Demichelis F; Fall K; Perner S; Andrén O; Schmidt F; Setlur SR; Hoshida Y; Mosquera JM; Pawitan Y; Lee C; Adami HO; Mucci LA; Kantoff PW; Andersson SO; Chinnaiyan AM; Johansson JE; Rubin MA
Oncogene; 2007 Jul; 26(31):4596-9. PubMed ID: 17237811
[TBL] [Abstract][Full Text] [Related]
4. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
Winnes M; Lissbrant E; Damber JE; Stenman G
Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040
[TBL] [Abstract][Full Text] [Related]
5. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer.
Wang J; Cai Y; Ren C; Ittmann M
Cancer Res; 2006 Sep; 66(17):8347-51. PubMed ID: 16951141
[TBL] [Abstract][Full Text] [Related]
6. [Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].
Dai MJ; Chen LL; Zheng YB; Chen W; Tao ZH; Weng ZL; Wu XL; Li CD; Chen ZG; Chen XD; Shi SB
Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(10):669-73. PubMed ID: 18642766
[TBL] [Abstract][Full Text] [Related]
7. ETS gene fusions in prostate cancer: from discovery to daily clinical practice.
Tomlins SA; Bjartell A; Chinnaiyan AM; Jenster G; Nam RK; Rubin MA; Schalken JA
Eur Urol; 2009 Aug; 56(2):275-86. PubMed ID: 19409690
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer.
Hofer MD; Kuefer R; Maier C; Herkommer K; Perner S; Demichelis F; Paiss T; Vogel W; Rubin MA; Hoegel J
Cancer Res; 2009 Jan; 69(2):640-6. PubMed ID: 19147579
[TBL] [Abstract][Full Text] [Related]
9. Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug development.
Attard G; Ang JE; Olmos D; de Bono JS
J Clin Pathol; 2008 Aug; 61(8):891-6. PubMed ID: 18495790
[TBL] [Abstract][Full Text] [Related]
10. Detection of the TMPRSS2-ETS fusion gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and paraffin-embedded samples with clinical data.
Rouzier C; Haudebourg J; Carpentier X; Valério L; Amiel J; Michiels JF; Pedeutour F
Cancer Genet Cytogenet; 2008 May; 183(1):21-7. PubMed ID: 18474293
[TBL] [Abstract][Full Text] [Related]
11. The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications.
Shah RB; Chinnaiyan AM
Adv Anat Pathol; 2009 May; 16(3):145-53. PubMed ID: 19395877
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence.
Hawksworth D; Ravindranath L; Chen Y; Furusato B; Sesterhenn IA; McLeod DG; Srivastava S; Petrovics G
Prostate Cancer Prostatic Dis; 2010 Dec; 13(4):311-5. PubMed ID: 20820186
[TBL] [Abstract][Full Text] [Related]
13. ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer.
Turner DP; Watson DK
Expert Rev Anticancer Ther; 2008 Jan; 8(1):33-42. PubMed ID: 18095881
[TBL] [Abstract][Full Text] [Related]
14. [Frequent gene fusion in prostate cancer: clinical applications in diagnosis, prognosis and therapy].
Schmidt F; Scheble V; Mertz K; Perner S; Rubin MA
Dtsch Med Wochenschr; 2009 Jul; 134(28-29):1483-6. PubMed ID: 19572250
[TBL] [Abstract][Full Text] [Related]
15. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.
Tomlins SA; Mehra R; Rhodes DR; Smith LR; Roulston D; Helgeson BE; Cao X; Wei JT; Rubin MA; Shah RB; Chinnaiyan AM
Cancer Res; 2006 Apr; 66(7):3396-400. PubMed ID: 16585160
[TBL] [Abstract][Full Text] [Related]
16. Molecular biology of prostate-cancer pathogenesis.
Shand RL; Gelmann EP
Curr Opin Urol; 2006 May; 16(3):123-31. PubMed ID: 16679847
[TBL] [Abstract][Full Text] [Related]
17. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis.
Rostad K; Hellwinkel OJ; Haukaas SA; Halvorsen OJ; Øyan AM; Haese A; Budäus L; Albrecht H; Akslen LA; Schlomm T; Kalland KH
APMIS; 2009 Aug; 117(8):575-82. PubMed ID: 19664128
[TBL] [Abstract][Full Text] [Related]
18. Molecular markers of prostate cancer outcome.
Quinn DI; Henshall SM; Sutherland RL
Eur J Cancer; 2005 Apr; 41(6):858-87. PubMed ID: 15808955
[TBL] [Abstract][Full Text] [Related]
19. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.
Perner S; Mosquera JM; Demichelis F; Hofer MD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; De Marzo AM; Rubin MA
Am J Surg Pathol; 2007 Jun; 31(6):882-8. PubMed ID: 17527075
[TBL] [Abstract][Full Text] [Related]
20. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.
Helgeson BE; Tomlins SA; Shah N; Laxman B; Cao Q; Prensner JR; Cao X; Singla N; Montie JE; Varambally S; Mehra R; Chinnaiyan AM
Cancer Res; 2008 Jan; 68(1):73-80. PubMed ID: 18172298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
